News
Crystal Pharmatech | Reflecting on 2025
21 Feb 2026
en
Crystal Pharmatech is returning to DCAT Week with expanded capabilities. We have grown into a global CDMO with 300+ scientists across the US, Canada, and China, having supported over 2,000 NCEs to date. While we remain leaders in avoiding early-stage CMC pitfalls, we now offer true "Molecule to Medicine" support across three specialized platforms.
We invite you to discuss how our three specialized platforms can de-risk your 2026 development goals:
Small Molecules: From solid-state research and preformulation to GMP manufacturing (First-Time-Right approach).
Biologics (Crystal Bio Solutions): Bioanalytical testing, biomarker analysis, and CMC analytics.
Nucleic Acids (Crystal NAX): End-to-end solutions for nucleic acid therapeutics.
We are hosting private strategy sessions to help you navigate your upcoming CMC and development milestones.
Alex Chen, Ph.D.
Co-founder & CEO
Crystal Pharmatech
Robert Wenslow, Ph.D.
Co-founder and CBO
Crystal Pharmatech
Yongqiang Li, Ph.D.
CEO of Canada CDMO BU
Candoo Pharmatech
Derik McCathy
Subject Matter Expert
Crystal Pharmatech
Schedule a meeting with our experts.
When: March 23-26, 2026
Where: The Benjamin Royal Sonesta New York (125 E 50th St, New York, NY 10022)
Find Us: Suite 2001
Ready for an evening of unscripted connection?
Please complete the form to register for our San Diego Biotech and Pharma R&D social. Note: Registration is subject to review. You will receive a formal confirmation email once your attendance is approved.
By providing your e-mail address, you agree to receive an e-mail response from Crystal Pharmatech to your registration. The information you submit will be governed by our Privacy Policy.
_.webp "A Significant Step Toward Greater Clarity in Polymorph Control for Innovative Drugs")
Subscribe to be the first to get the updates!
